Strike One against CLASSBy Grace-Marie TurnerSpeaker Boehner lead the House of Representatives on Wednesday to overwhelmingly pass a bill repealing the long-term care entitlement in ObamaCare -- the one that Democratic leaders have described as "completely unsustainable" and "a Ponzi scheme of the first order" and which the Obama administration could see "no viable path forward" to implement. The vote to repeal the CLASS Act was 267-159, with 28 Democrats joining 239 voting Republicans in passing the repeal bill, which now heads to the Senate for an uncertain fate. President Obama has vowed to veto any efforts to strike the program from his health overhaul law, even though there is considerable risk to the administration for keeping the program on the books. The Congressional Research Service has said the courts could order CLASS to be implemented even if it is financially unsustainable. Repeal is essential. Sen. Jay Rockefeller (D-WV) said after the vote: "In the past, lawmakers would have worked together to amend existing law to address a serious national crisis like long-term care." What he likely means is that if the individual mandate is upheld by the Supreme Court, he'll come back to force us to buy the long-term care coverage so the program can survive. CLASS (the Community Living Assistance Services and Supports) Act would pay $50 a day -- $18,250 a year -- for long-term care services for anyone who had paid premiums for five years. Participation was voluntary, and it was inevitable that the program would attract older, sicker people, sending CLASS into a death spiral. Some estimates concluded premiums would have had to be $3,000 a month for the program to break even. Since participation is voluntary, HHS could not figure out a way to guarantee the program would be fiscally sound for 75 years without taxpayer bailouts, a requirement that former Sen. Judd Gregg (R-NY) managed to get into the health law. But news of the program's demise was a slap in the face to CLASS advocates, who knew it was in trouble but were surprised that the program got a death certificate when the administration pulled the plug on implementing it last fall. A recent article lamenting its failure inadvertently admitted the core problem with the law: Howard Gleckman of the Urban Institute wrote in the journal Health Affairs: "[T]he law allowed low-income people to purchase coverage for just $5 a month. That meant that many enrollees could pay just $300 over five years and receive at least $18,000 a year in benefits for the rest of their lives."
People need long-term care insurance, but this isn't it. Full repeal of CLASS is the only way to protect future generations from another entitlement tsunami. 
One of our countless concerns with growing government control over the health sector is additional bureaucratic delay in getting new treatments to patients. We're seeing more and more evidence of these hurdles. And we have another example. The Food and Drug Administration expedited approval of a new vaccine, called Prevnar 13, which prevents pneumonia and related diseases in people over age 50 by targeting the most common pneumonia bacterium (Streptococcus pneumoniae). The FDA approved the use of Prevnar 13 in December under its "accelerated approval pathway," which allows for faster consideration of treatments for serious and life-threatening illnesses. At least 300,000 adults are hospitalized each year because they contract this form of pneumonia and at least 5,000 of them die. "Pneumococcal disease is a substantial cause of illness and death," the FDA wrote in its release. "Today's approval provides an additional vaccine" for this disease. So you should be able to get it right away, right? Wrong. There is yet another hurdle -- the Centers for Disease Control and Prevention. The CDC's Advisory Committee on Immunization Practices (ACIP) apparently does not share the FDA's sense of urgency in getting this life-saving medicine to patients. In its meeting later this month, Prevnar 13 is slated only for "Information and Discussion" but not a vote. That's important because ACIP votes to decide what vaccines to recommend for the adult immunization schedule. Public programs like Medicare and private insurers rely on ACIP for guidance on what vaccines they will pay for. No vote. No vaccine. ACIP only meets three times a year. If it doesn't vote on the vaccine during its February meeting, then it will be June until a vote could be held. That means at least 100,000 adults could be hospitalized unnecessarily and more than 1,500 could die waiting for the government agency to act. The vaccine has been approved by the FDA as safe and the FDA put it on its "accelerated approval pathway" to get it to patients faster. Prevnar 13 already has been approved for use in children age 6 weeks to 5 years old, and administration of the vaccine supports the government's Healthy People 2020 objectives. A delay is not just another bureaucratic hurdle. It can cost lives. CLIPS OF THE WEEKSally Pipes on what could replace ObamaCareSally Pipes of the Pacific Research Institute talks about her new book, The Pipes Plan, to replace ObamaCare's expensive government health care bureaucracies with a market-driven system that would offer better treatment to patients while saving taxpayers money. Watch now >> 
State of the Union Policy SeriesAmerican Enterprise Institute health policy scholars, Thomas Miller, Joe Antos, and Bob Helms discuss health and budget policy challenges in this forum on the State of the Union. Watch now >> 
back to top |
No comments:
Post a Comment